Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer

Area of Science:

• Gastroenterology and Oncology
• Surgical Innovation
• Systemic Therapy

Background:

• Gastric cancer presents a significant global health challenge, particularly in East Asia.
• Multimodal treatment strategies are evolving rapidly.
• Recent updates focus on surgical, chemotherapeutic, immunotherapeutic, and nutritional interventions.

Purpose of the Study:

• To review key advancements in gastric cancer management from 2023-2024.
• To summarize innovations in surgical techniques, perioperative therapies, and nutritional support.
• To discuss evolving treatment strategies for early, advanced, and stage IV gastric cancer.

Main Methods:

• Review of recent (2023-2024) literature and clinical trials.
• Focus on surgical innovations (laparoscopic, robotic gastrectomy).
• Analysis of perioperative systemic therapies (chemotherapy, immunotherapy) and nutritional interventions.

Main Results:

• Laparoscopic and robotic gastrectomy are widely adopted in Asia.
• Perioperative chemotherapy (FLOT, SOX, XELOX, DOS) is standard; immunotherapy shows promise.
• Advanced nutritional strategies and digital tools improve patient outcomes.
• Stage IV gastric cancer management includes chemotherapy, conversion surgery, and oligometastasis treatment.

Conclusions:

• Integration of molecular biomarkers (HER2, PD-L1, MSI, ctDNA), precise staging, and multidisciplinary collaboration are crucial for personalized gastric cancer treatment.
• Ongoing trials and international cooperation will further refine evidence-based care.
• Optimized perioperative nutrition and digital health tools enhance patient outcomes.